Diamond Shruumz Microdosing Candy Under FDA Investigation for Death

Diamond Shruumz microdosing candy is under FDA investigation after new reports emerged about a connection to a death that was “potentially associated” with the controversial treat.

The Associated Press reports that the candy has now been officially recalled because it contains muscimol, a toxin found in some mushrooms. There is some speculation that the active ingredient could be linked to the death, along with 27 reported hospitalizations.

Seizures, anxiety, irregular heart rhythms, and loss of consciousness were among the serious symptoms recorded by those who became unwell. According to FDA officials, the most recent ailment was reported on Monday, July 1.

Furthermore, after consuming chocolate bars, cones, and candies bearing the Diamond Shruumz trademark, at least 48 individuals in 24 states have reported being ill.

Last month, Diamond Shruumz pushed back at claims that its controversial candy was dangerous, claiming that it was a “safe and enjoyable experience” and free of psychoactive drugs.

“There is no presence of psilocybin, amanita, or any scheduled drugs, ensuring a safe and enjoyable experience. Rest assured, our treats are not only free from psychedelic substances, but our carefully crafted ingredients still offer an experience,” read a statement on the company’s website.

But at the same time, six people were hospitalized due to allegedly overdosing on the product. The FDA then issued a public alert about the candy.

“FDA is working to determine the cause of these illnesses and is considering the appropriate next steps. More information will be provided as it becomes available,” the statement in the alert read.

The market for microdosing has grown significantly in recent years as companies try to get medications like MDMA licensed for medical usage. Business Insider refers to the year 2020 as a “psychedelics renaissance” due to the spike in interest in psychedelics. According to Pitchbook data, over the first three quarters of that year, investments in psychedelic startups totaled $163.6 million.

Microdosing is the practice of frequently ingesting minute doses of a drug — typically a psychedelic — without feeling any effects.

Some people believe that microdosing can improve mental health and creativity. The practice has gained traction in Silicon Valley, where a number of CEOs have included microdosing into their regular morning routines.